The CentraSight Treatment Program allows patients to see again by implanting a tiny telescope in the eye in an outpatient procedure, then coordinating with low vision specialists to help the patient learn how to use their new vision for everyday activities.
VisionCare Ophthalmic Technologies, the developer of the CentraSight telescope implant, recently published five-year study data that demonstrates the long-term effectiveness and safety of the telescope implant for macular degeneration in patients 65 and older. The data supports the October 2014 decision by the U.S. Food and Drug Administration (FDA) to expand the eligibility for the telescope implant to patients 65 and older. The telescope implant is the only FDA-approved, Medicare-eligible device to treat the most advanced form of AMD.
To find our more, please go to www.CentraSight.com or call 1-877-99SIGHT.